BioXcel Granted Patent for Dexmedetomidine Use

An announcement from Bioxcel Therapeutics ( (BTAI) ) is now available.

On July 15, 2025, BioXcel Therapeutics announced that the U.S. Patent and Trademark Office allowed a patent application related to a single dose administration of dexmedetomidine for treating acute agitation in schizophrenia or bipolar disorder patients with specific QT prolongation criteria. This patent, once issued, will be listed in the Orange Book for Igalmi, marking the 14th such listing, and will expire on January 12, 2043, potentially impacting the company’s market positioning by strengthening its intellectual property portfolio.

The most recent analyst rating on (BTAI) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.

Spark’s Take on BTAI Stock

According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.

Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.

To see Spark’s full report on BTAI stock, click here.

More about Bioxcel Therapeutics

BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative medicines for neuropsychiatric disorders and immuno-oncology. The company’s primary products include treatments for acute agitation and other central nervous system disorders, with a market focus on addressing unmet medical needs in these areas.

Average Trading Volume: 280,775

Technical Sentiment Signal: Sell

Current Market Cap: $11.93M

For an in-depth examination of BTAI stock, go to TipRanks’ Overview page.